Keyphrases
Atrial Fibrillation
100%
Minor Bleeding
100%
Non-vitamin K Antagonist Oral Anticoagulants
100%
Oral Anticoagulant Therapy
33%
Dabigatran
33%
Rivaroxaban
33%
Apixaban
33%
Novel Anticoagulants
22%
HAS-BLED Score
22%
International Society
11%
Risk Factors
11%
Consecutive Patients
11%
Clinically Significant
11%
Drug Use
11%
Overall Rate
11%
Thrombosis
11%
Observational Cohort Study
11%
Bleeding
11%
Ischemic Stroke
11%
Outpatient Clinic
11%
Hematoma
11%
Anticoagulant Drugs
11%
Risk Indicators
11%
Identify Risk
11%
Hemostasis
11%
Non-majors
11%
Bleeding Rate
11%
Anticoagulant Use
11%
Bleeding Risk
11%
Vitamin K Antagonists
11%
Retrospective Observational Study
11%
Randomized Setting
11%
Outpatient Unit
11%
Nosebleed
11%
Bruise
11%
Stroke Prophylaxis
11%
Overt Bleeding
11%
Medicine and Dentistry
Atrial Fibrillation
100%
Bleeding
100%
Vitamin K Antagonist
100%
Antithrombotic
100%
Ciclonicate
36%
Anticoagulant Therapy
27%
Rivaroxaban
27%
Apixaban
27%
Dabigatran
27%
Outpatient
18%
Population Research
9%
Cohort Study
9%
Observational Study
9%
Hematoma
9%
Brain Ischemia
9%
Drug Use
9%
Thrombosis
9%
Blood Stasis
9%
Epistaxis
9%
Bruise
9%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Bleeding
100%
Antivitamin K
100%
Anticoagulant Agent
100%
Ciclonicate
36%
Rivaroxaban
27%
Dabigatran
27%
Apixaban
27%
Brain Ischemia
9%
Observational Study
9%
Cohort Study
9%
Hematoma
9%
Population Study
9%
Blood Stasis
9%
Thrombosis
9%
Epistaxis
9%